Novavax's RSV vaccine misses in Phase III in infants

Novavax Inc. (NASDAQ:NVAX) said its ResVax RSV vaccine missed the primary endpoint in the Phase III Prepare trial to prevent respiratory syncytial virus infection in infants via maternal immunization.

In the trial's per protocol population (n=4,195), ResVax showed a vaccine efficacy of 39.4% vs. placebo in reducing the incidence of medically significant RSV lower respiratory tract infections through 90 days of life...